Analyst Lili (Aurélie) Nsongo of Leerink Partners maintained a Buy rating on Voyager Therapeutics, with a price target of $12.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lili (Aurélie) Nsongo’s rating is based on several strategic and financial developments at Voyager Therapeutics. The company has extended its cash runway guidance to 2028 through a restructuring plan that includes workforce reductions and operational efficiencies. This restructuring is expected to streamline clinical trial designs and outsource certain functions, thereby optimizing resources.
Additionally, Voyager is making significant progress in its pipeline, with ongoing dosing in the final cohort of a Phase 1/2 study for its anti-tau antibody VY7523 in Alzheimer’s patients, and plans for an IND filing for its siRNA therapy VY1706 in 2026. The company also stands to benefit from potential milestone payments of up to $35 million from partnered programs with NBIX, which are on track for IND filings by the end of 2025. These factors, combined with a solid cash position of $262 million, underpin the Buy rating.
According to TipRanks, (Aurélie) Nsongo is an analyst with an average return of -29.4% and a 18.18% success rate. (Aurélie) Nsongo covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics, Voyager Therapeutics, and Sensorion SAS.
In another report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $12.00 price target.